» Articles » PMID: 39757503

A Simple Endoscopic Score for Crohn's Disease (SES-CD) ≥ 7 Predicts Disease Progression

Abstract

Background: Up to 30% of patients with Crohn's disease (CD) will experience a mild disease course. However, there is no consensus definition for mild CD.

Aim: To examine the Simple Endoscopic Score for Crohn's disease (SES-CD) thresholds best associated with low likelihood of long-term disease progression.

Methods: We conducted a multicentre retrospective cohort study at three tertiary care centres in United States and Europe. We analysed data from 177 surgery-naïve patients with CD who had endoscopic assessment while not on immunosuppressive therapy. The primary outcome was disease progression (systemic steroids, biologic or immunomodulator therapy initiation; new stricturing or penetrating complications; or CD-related hospitalisation or surgery). Univariable and multivariable Cox proportional hazards modelling identified predictors of the primary outcome at 2 and 5 years following endoscopy.

Results: Disease progression occurred in 23% and 35% of patients at years two and five, respectively. Endoscopic severity at enrolment independently predicted disease progression. Compared to those with an SES-CD of 0, an SES-CD ≥ 7 had a greater risk of progression at 2 years (HR 2.50, 95% CI 1.09-5.72) and 5 years (HR 2.89, 95% CI 1.41-5.91). SES-CD > 7 remained independently predictive of disease progression among the 129 immunosuppression-naïve patients (HR 5.65, 95% CI 1.49-21.52) and after excluding patients with prior penetrating disease (HR 2.32, 95% CI 1.00-5.45).

Conclusions: SES-CD ≥ 7 predicts disease progression in mild CD. A score ≤ 6 may help identify patients less likely to progress and be part of the definition of mild CD.

References
1.
Peyrin-Biroulet L, Reinisch W, Colombel J, Mantzaris G, Kornbluth A, Diamond R . Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut. 2013; 63(1):88-95. DOI: 10.1136/gutjnl-2013-304984. View

2.
Argmann C, Hou R, Ungaro R, Irizar H, Al-Taie Z, Huang R . Biopsy and blood-based molecular biomarker of inflammation in IBD. Gut. 2022; 72(7):1271-1287. PMC: 10014487. DOI: 10.1136/gutjnl-2021-326451. View

3.
Daperno M, DHaens G, Van Assche G, Baert F, Bulois P, Maunoury V . Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004; 60(4):505-12. DOI: 10.1016/s0016-5107(04)01878-4. View

4.
Khanna R, Bouguen G, Feagan B, DHaens G, Sandborn W, Dubcenco E . A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design. Inflamm Bowel Dis. 2014; 20(10):1850-61. DOI: 10.1097/MIB.0000000000000131. View

5.
Zabana Y, Garcia-Planella E, Van Domselaar M, Manosa M, Gordillo J, Lopez-Sanroman A . Predictors of favourable outcome in inflammatory Crohn's disease. A retrospective observational study. Gastroenterol Hepatol. 2013; 36(10):616-23. DOI: 10.1016/j.gastrohep.2013.07.004. View